Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shree Ganesh Remedies Ltd reported Q4FY25 revenue of ₹24.43 crore, down 35% YoY, with EBITDA falling 42% to ₹9.88 crore and PAT declining 48% to ₹6.60 crore. For full year FY25, revenue declined 14% YoY to ₹108.60 crore, while PAT fell 18% to ₹23.10 crore. Management attributed the drop to a European market slowdown and a 25-30% reduction in domestic realisations due to intensified competition, though volumetric growth remained healthy. Full-year EBITDA margins expanded 290 bps YoY to 36.1%, aided by earlier CRAMS contract benefits. The PAT decline was compounded by higher depreciation and finance costs from the newly commissioned Plant 8. The company announced a new MOU with a Japanese client for a speciality chemical, secured approved-source status for an agrochemical product in Europe, and is building a new pilot plant targeted to begin operations in Q2 FY26.
Near-term margin compression from a repriced CRAMS contract and weak European demand may pressure the stock, but new client wins, capacity expansion, and rising enquiries as global clients diversify away from China offer meaningful long-term growth optionality.